OTCPK:PSID

Stock Analysis Report

Executive Summary

PositiveID Corporation, a life sciences and technology company, develops and sells molecular diagnostic systems for bio-threat detection and medical testing in the United States and internationally.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has PositiveID's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

PSID

-0.4%

US Medical Equipment

1.0%

US Market


1 Year Return

-80.0%

PSID

12.8%

US Medical Equipment

6.7%

US Market

Return vs Industry: PSID underperformed the US Medical Equipment industry which returned 12.8% over the past year.

Return vs Market: PSID underperformed the US Market which returned 6.7% over the past year.


Share holder returns

PSIDIndustryMarket
7 Day0%-0.4%1.0%
30 Day0%-2.7%-1.8%
90 Day0%-0.3%-1.8%
1 Year-80.0%-80.0%13.7%12.8%9.1%6.7%
3 Year-100.0%-100.0%70.0%64.8%46.1%36.6%
5 Year-100.0%-100.0%130.9%105.1%66.9%48.6%

Price Volatility Vs. Market

How volatile is PositiveID's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is PositiveID undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether PositiveID is trading at an attractive price based on the cash flow it is expected to produce in the future. But as PositiveID has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of PSID’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through PositiveID regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is PositiveID expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PositiveID has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of PSID’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access PositiveID's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has PositiveID performed over the past 5 years?

17.0%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, PositiveID has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

  • When a company lacks a financial track record, its management’s track record becomes important. Corporate governance also plays an important role in a young business as board members are seen as highly-experienced leaders to help steer the company into the future. Take a look at PositiveID's' management and board experience and expertise to assess their ability to deliver on their strategic promises.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access PositiveID's filings and announcements here.
  • Explore strong past performing companies in the Healthcare industry.

Financial Health

How is PositiveID's financial position?


Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if PSID's short term assets cover its short term liabilities

Long Term Liabilities: PSID has no long term liabilities


Debt to Equity History and Analysis

Debt Level: PSID is debt free.

Reducing Debt: PSID currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: Insufficient data to determine if PSID has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if PSID's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if PSID has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PSID has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is PositiveID's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate PSID's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PSID's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PSID's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PSID's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PSID's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of PositiveID's salary, the management and board of directors tenure and is there insider trading?

7.8yrs

Average board tenure


CEO

William Caragol (52yo)

8.2yrs

Tenure

US$332,394

Compensation

Mr. William J. Caragol has been the Chief Executive Officer of PositiveID Corporation at MicroFluidic Systems since August 26, 2011 and its Acting Chief Financial Officer since September 28, 2012. Mr. Cara ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether William's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare William's compensation with company performance.


Board Age and Tenure

7.8yrs

Average Tenure

52yo

Average Age

Experienced Board: PSID's board of directors are considered experienced (7.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • William Caragol (52yo)

    Chairman

    • Tenure: 8.2yrs
    • Compensation: US$332.39k
  • Allison Tomek

    Senior VP of Corporate Development & Secretary

    • Tenure: 0yrs
  • Gary O'Hara (69yo)

    Chief Technology Officer

    • Tenure: 0yrs
  • Kimothy Smith

    Chief Technology Advisor & Member of Advisory Board

    • Tenure: 0yrs

Board Members

  • Michael Krawitz (49yo)

    Director

    • Tenure: 10.9yrs
    • Compensation: US$70.00k
  • Jeffrey Cobb (57yo)

    Director

    • Tenure: 12.6yrs
    • Compensation: US$70.00k
  • Mike Campbell (49yo)

    Member of Board of Advisors

    • Tenure: 5.8yrs
  • William Caragol (52yo)

    Chairman

    • Tenure: 8.2yrs
    • Compensation: US$332.39k
  • Ned Siegel (67yo)

    Director

    • Tenure: 8.7yrs
    • Compensation: US$70.00k
  • Yuval Rabin (64yo)

    Member of Board of Advisors

    • Tenure: 0yrs
  • Kimothy Smith

    Chief Technology Advisor & Member of Advisory Board

    • Tenure: 0yrs
  • Benedikt Von Braunmühl (51yo)

    Member of Board of Advisors

    • Tenure: 3.4yrs
  • R. Schaudies

    Member of Board of Advisors

    • Tenure: 3.2yrs

Company Information

PositiveID Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PositiveID Corporation
  • Ticker: PSID
  • Exchange: OTCPK
  • Founded: 2001
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$222.163k
  • Shares outstanding: 2.22b
  • Website: https://www.psidcorp.com

Number of Employees


Location

  • PositiveID Corporation
  • 1690 South Congress Avenue
  • Suite 201
  • Delray Beach
  • Florida
  • 33445
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PSIDOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2007

Biography

PositiveID Corporation, a life sciences and technology company, develops and sells molecular diagnostic systems for bio-threat detection and medical testing in the United States and internationally. It ope ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 01:57
End of Day Share Price2019/10/11 00:00
Earnings2018/03/31
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)